research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
Search
for
Sort by
Research
60-90 / 1000+ results research Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta‐Analysis
Intralesional dutasteride improves hair growth in androgenic alopecia with minimal side effects.
research Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management
Both treatment combinations improved hair growth similarly and were safe.
research Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
research Comparative Evaluation of Efficacy Between Topical Calcipotriol Used Along With Topical Clobetasol And Topical Clobetasol Monotherapy In Treatment Of Alopecia Areata: A Randomised Clinical Trial
Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
research ADT-G as a promising biomarker for peripheral hyperandrogenism in adult female acne
ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.
research Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy
Low-dose oral minoxidil does not increase pericardial effusions in alopecia patients.
research Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
Alopecia areata treatments often don't lead to lasting improvement.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research Findings from the assessment of real-world disease characteristics and outcomes in alopecia areata in a global non-interventional observational cohort (ADAAGIO) study
Most patients with alopecia areata did not achieve lasting hair regrowth despite treatment.
research Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids.
Patients treated with long-term intralesional corticosteroids for alopecia areata should be monitored for bone density changes and advised on osteoporosis prevention.
research Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
research Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series
research The evaluation of the quality of life in women with androgeneticalopecia using hairdex
Androgenetic alopecia significantly affects women's emotions, especially older women.
research BH08 Evaluating quality-of-life measures for alopecia: a comparative analysis of Dermatology Life Quality Index and Hospital Anxiety and Depression Scale correlations with disease severity
DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.
research 180 Impact of underlying medical conditions and medications on edema development in alopecia patients receiving low-dose oral minoxidil (LDOM)
Low-dose oral minoxidil is safe for alopecia patients, even those prone to edema.
research An anti‐hair loss treatment in the management of mild androgenetic alopecia: results from a large, international observational study
AC5 improves hair loss and hair quality with high satisfaction rates.
research Outcome of Dutasteride 0.5mg in Androgenic Alopecia
Dutasteride 0.5mg improves hair growth in 78% of people with hair loss, but may cause sexual problems in some.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo‐controlled study
Microneedling with topical dutasteride improves hair growth in men with hair loss and is safe to use.
research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research Diffuse hair loss in Addison disease: A reason for X-linked adrenoleukodystrophy screening
Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Low-Dose Systemic Methotrexate Therapy for Recalcitrant Alopecia Areata
Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
research Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response
Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.